Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    systematic_literature_reviews_whitepaper
    Demystifying the SLR: “S” stands for systematic

    A structured approach to evidence-based decision-making.

    biosimilars and oncology
    The future of oncology biosimilars

    Considerations for development through 2040.

    icons connected through network_artificail_intelligence
    Decoding AI in software as a medical device (SaMD)

    Regulatory insights and market strategies.

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Enhancing clinical trials in obesity by integrating COAs and DHTs

    7 October 2025. Register now.

    whitepaper CNS
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    22 October 2025. Register now.

  • About ICON
    About ICON
    Company history ICON at a glance Healthcare Intelligence ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Medical analytics presentation preview
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Events
  4. Webinars
  5. Addressing the Challenges of Type II Diabetes

Addressing the Challenges of Type II Diabetes

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Learn about analytical test solutions for Type II Diabetes that enable the creation of high quality laboratory data sets

  • Date 26 April 2017
    Time 11:00 - 12:00
    Location Webinar
    Timezone America/Bogota

    Join ICON’s expert Dr. Andrew Roche, PhD as he speaks about overcoming challenges when developing Diabetes trials. Addressing these challenges via use of high quality tools is critical to successful completion of a clinical trial.

On-Demand Webinar Archive

To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.

Access Webinar Archive

Overview

It is the belief of ICON Central Laboratories that these considered solutions will provide high quality options that will increase the opportunity for success for those undertaking the challenge posed by drug development.

Key insights include:

  • The creation of high quality laboratory data sets as a means of enabling an accurate and efficient assessment of the test compound. 
  • Understanding the value of  global laboratory harmonisation when performing global clinical trial. 
  • Accurately defining clinical status via laboratory endpoints. 

Key speakers

Dr. Andrew Roche, PhD

Scientific Director, Global Validation, Scientific Affairs

Andrew, a PhD with in depth knowledge of the intricacies of analytical methods and their applications within clinical trials, oversees the Scientific Affairs and Global Validations functions of ICON Central Laboratories.  

Andrew has over 15 years’ experience in the clinical trial industry. He began his career within the infectious disease arena of biotech where he successfully led projects designed to identify and validate large molecule drug targets within pathogenic microorganisms. Andrew then moved into the field of biomarkers and led projects that created marketed immunoassay products for the detection of novel biomarkers of organ toxicity. Prior to joining ICON Andrew co-founded a bioanalytical CRO dedicated to the development, validation and utilization of customised methods for the quantification of large molecule drugs, anti-drug antibodies and biomarkers.

Andrew holds a B.A. Mod, and Ph.D. in Medical Microbiology from Trinity College Dublin and has authored several scientific publications.  In his current role as Scientific Director he focuses on the intricacies of analytical methods and their applications within clinical trials with the goal of facilitating the creation of an accurate and precise analytical data set thereby facilitating an accurate clinical assessment of analytical data.

Target audience

This program is intended for senior professionals from biopharmaceutical companies working within diabetes clinical research. 

In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?